ES2595240T3 - Derivados de tetrahidroquinazolinona como inhibidores de PARP - Google Patents
Derivados de tetrahidroquinazolinona como inhibidores de PARP Download PDFInfo
- Publication number
- ES2595240T3 ES2595240T3 ES13742752.2T ES13742752T ES2595240T3 ES 2595240 T3 ES2595240 T3 ES 2595240T3 ES 13742752 T ES13742752 T ES 13742752T ES 2595240 T3 ES2595240 T3 ES 2595240T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- spiro
- alkyl
- dihydro
- piperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
INKO07622012 | 2012-07-09 | ||
IN762KO2012 | 2012-07-09 | ||
PCT/IB2013/055618 WO2014009872A1 (en) | 2012-07-09 | 2013-07-09 | Tetrahydroquinazolinone derivatives as parp inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2595240T3 true ES2595240T3 (es) | 2016-12-28 |
Family
ID=48906465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13742752.2T Active ES2595240T3 (es) | 2012-07-09 | 2013-07-09 | Derivados de tetrahidroquinazolinona como inhibidores de PARP |
Country Status (8)
Country | Link |
---|---|
US (1) | US9359367B2 (pt) |
EP (1) | EP2870140B8 (pt) |
AU (1) | AU2013288265B2 (pt) |
CA (1) | CA2877826C (pt) |
ES (1) | ES2595240T3 (pt) |
IN (1) | IN2015MN00002A (pt) |
WO (1) | WO2014009872A1 (pt) |
ZA (1) | ZA201409497B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016023397B1 (pt) * | 2014-04-10 | 2022-08-16 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Composto da fórmula ou um sal farmaceuticamente aceitável |
WO2016012956A1 (en) * | 2014-07-24 | 2016-01-28 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
WO2017013593A1 (en) | 2015-07-22 | 2017-01-26 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
KR20180037265A (ko) * | 2015-08-17 | 2018-04-11 | 루핀 리미티드 | Parp 억제제로서의 헤테로아릴 유도체 |
CN108822115B (zh) * | 2017-04-21 | 2022-08-12 | 上海迪诺医药科技有限公司 | 一种抑制parp活性的化合物的制备方法及其中间体 |
HUE061595T2 (hu) | 2017-12-21 | 2023-07-28 | Ribon Therapeutics Inc | Kinazolinonok mint PARP14 inhibitorok |
CN111269216A (zh) * | 2018-12-05 | 2020-06-12 | 中国医学科学院药物研究所 | 含有哌嗪酮的喹唑啉二酮盐类化合物、其制备方法、药物组合物和用途 |
TWI749881B (zh) * | 2019-11-21 | 2021-12-11 | 大陸商深圳信立泰藥業股份有限公司 | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 |
CN112608303B (zh) * | 2020-12-25 | 2021-10-26 | 华南理工大学 | 一种哌嗪类中间体及其制备方法与应用 |
CN114044769B (zh) * | 2021-11-25 | 2023-12-12 | 中山大学 | 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2027645A1 (de) | 1970-06-05 | 1971-12-09 | Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz | Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
BE503170A (pt) | 1975-09-02 | |||
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
IL90858A (en) | 1988-07-07 | 1994-08-26 | Rhone Poulenc Sante | History (Aza) Naftalensultam, their preparation and preparations containing them |
DE4312832C1 (de) | 1993-04-20 | 1994-10-20 | Boehringer Ingelheim Kg | Verfahren zur Herstellung enantiomerenreiner Ketale der (S)- und (R)-3-Oxocyclopentancarbonsäure |
DE4316576A1 (de) | 1993-05-18 | 1994-11-24 | Boehringer Ingelheim Kg | Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin |
US5589489A (en) | 1993-12-15 | 1996-12-31 | Zeneca Limited | Cyclic amide derivatives for treating asthma |
GB9904275D0 (en) | 1999-02-24 | 1999-04-21 | Cancer Res Campaign Tech | Anti-cancer compounds |
AU2001249262A1 (en) | 2000-03-20 | 2001-10-03 | Sepracor, Inc. | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof |
DE60102106T2 (de) | 2000-08-03 | 2004-07-15 | Pfizer Products Inc., Groton | Diazacyclooctanverbindungen und ihre therapeutische Verwendung |
AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
JPWO2002094790A1 (ja) | 2001-05-23 | 2004-09-09 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
IL159808A0 (en) | 2001-07-11 | 2004-06-20 | Elan Pharm Inc | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
AUPR975601A0 (en) | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
US20040048853A1 (en) | 2002-08-21 | 2004-03-11 | Gustave Bergnes | Compounds, compositions, and methods |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
CN1266155C (zh) | 2003-08-01 | 2006-07-26 | 浙江震元制药有限公司 | 6-氯-4-羟基-2-甲基-2H-噻吩并(2,3-e)-1,2-噻嗪-1,1-二氧化物-3-羧酸酯的合成方法 |
BRPI0413555A (pt) | 2003-08-18 | 2006-10-17 | Lundbeck & Co As H | composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, método para o tratamento de uma doença, para a fabricação de um composto e para a preparação de composto |
US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
ES2371469T3 (es) | 2003-12-01 | 2012-01-03 | Kudos Pharmaceuticals Limited | Inhibidores de reparación de daños en adn para el tratamiento del cáncer. |
US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
JP4912145B2 (ja) | 2004-02-26 | 2012-04-11 | あすか製薬株式会社 | ピリミジン誘導体 |
US7381822B2 (en) | 2004-03-31 | 2008-06-03 | The General Hospital Corporation | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process |
US20050245534A1 (en) | 2004-04-29 | 2005-11-03 | Link James T | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
ES2389907T3 (es) | 2004-04-30 | 2012-11-02 | Takeda Pharmaceutical Company Limited | Compuesto de amida heterocíclica y uso del mismo como un inhibidor de MMP-13 |
ATE540936T1 (de) | 2004-06-30 | 2012-01-15 | Janssen Pharmaceutica Nv | Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer |
WO2006039545A2 (en) | 2004-09-30 | 2006-04-13 | Maxim Pharmaceuticals, Inc. | Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis |
JPWO2006051851A1 (ja) | 2004-11-10 | 2008-05-29 | わかもと製薬株式会社 | 2,3,4,5−テトラヒドロ−1h−1,5−ベンゾジアゼピン誘導体、及び、医薬組成物 |
BRPI0517426A (pt) | 2004-12-17 | 2008-10-07 | Astrazeneca Ab | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente |
PT1863787E (pt) | 2005-03-23 | 2011-07-29 | Actelion Pharmaceuticals Ltd | Derivados de benzo(c)tiofenos hidrogenados como imunomoduladores |
WO2006137510A1 (ja) | 2005-06-24 | 2006-12-28 | Ono Pharmaceutical Co., Ltd. | 脳血管障害時における出血低減剤 |
US7300947B2 (en) | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
CA2615380A1 (en) | 2005-07-15 | 2007-01-25 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
ES2361566T3 (es) | 2005-11-25 | 2011-06-20 | Pharma Mar S.A., Sociedad Unipersonal | Uso de inhibidores de parp-1. |
US20070197509A1 (en) | 2005-12-21 | 2007-08-23 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
CA2914168C (en) | 2006-03-28 | 2018-05-08 | Atir Holding S.A. | Pyrido[1,2-a]pyrimidin-4-one derivatives and their use in the treatment of sexual disorders |
TWI498332B (zh) | 2006-04-26 | 2015-09-01 | Hoffmann La Roche | 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物 |
WO2008080824A1 (en) | 2006-12-29 | 2008-07-10 | F. Hoffmann-La Roche Ag | Aromatic sulfonated ketals |
EP2208728A4 (en) | 2007-09-19 | 2011-12-21 | Inst Med Molecular Design Inc | HETEROCYCLIC DERIVATIVE DERIVATIVE DERIVATIVE TO 11 -? - HYDROXYSTEROIDDEHYDROGENASE TYPE I |
JP2009096804A (ja) | 2007-09-26 | 2009-05-07 | Santen Pharmaceut Co Ltd | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤 |
JP2009196973A (ja) | 2007-09-26 | 2009-09-03 | Santen Pharmaceut Co Ltd | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 |
US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
FR2926221A1 (fr) | 2008-01-14 | 2009-07-17 | Tassin Thomas | Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand. |
WO2009114459A2 (en) | 2008-03-10 | 2009-09-17 | The Trustees Of The University Of Pennsylvania | Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein |
EP2373653B1 (en) | 2008-12-05 | 2014-04-02 | F. Hoffmann-La Roche AG | Pyrrolopyrazinyl urea kinase inhibitors |
WO2010082813A1 (en) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
CA2792276A1 (en) | 2010-03-25 | 2011-09-29 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
ES2587657T3 (es) | 2010-09-03 | 2016-10-26 | Bayer Intellectual Property Gmbh | Derivados de dihidropirimidinona condensados sustituidos |
-
2013
- 2013-07-09 IN IN2MUN2015 patent/IN2015MN00002A/en unknown
- 2013-07-09 AU AU2013288265A patent/AU2013288265B2/en not_active Ceased
- 2013-07-09 WO PCT/IB2013/055618 patent/WO2014009872A1/en active Application Filing
- 2013-07-09 ES ES13742752.2T patent/ES2595240T3/es active Active
- 2013-07-09 EP EP13742752.2A patent/EP2870140B8/en not_active Not-in-force
- 2013-07-09 US US14/411,968 patent/US9359367B2/en not_active Expired - Fee Related
- 2013-07-09 CA CA2877826A patent/CA2877826C/en not_active Expired - Fee Related
-
2014
- 2014-12-23 ZA ZA2014/09497A patent/ZA201409497B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2877826C (en) | 2016-08-16 |
AU2013288265A1 (en) | 2015-01-29 |
CA2877826A1 (en) | 2014-01-16 |
AU2013288265B2 (en) | 2017-04-06 |
IN2015MN00002A (pt) | 2015-10-16 |
EP2870140A1 (en) | 2015-05-13 |
EP2870140B1 (en) | 2016-07-27 |
US20150152118A1 (en) | 2015-06-04 |
ZA201409497B (en) | 2015-12-23 |
US9359367B2 (en) | 2016-06-07 |
EP2870140B8 (en) | 2016-09-28 |
WO2014009872A1 (en) | 2014-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2595240T3 (es) | Derivados de tetrahidroquinazolinona como inhibidores de PARP | |
ES2914311T3 (es) | Compuestos bicíclicos y su uso en el tratamiento del cáncer | |
ES2940641T3 (es) | Compuestos que inhiben la proteína MCL-1 | |
ES2900306T3 (es) | Combinación que comprende un antagonista de EP4 y un inhibidor de puntos de control inmunitario | |
ES2944573T3 (es) | Antagonistas de TLR7/8 y usos de los mismos | |
TWI789381B (zh) | 雜環化合物 | |
BR112020022006A2 (pt) | piridazinonas como inibidores de parp7 | |
CA2829188C (en) | Dispiropyrrolidine derivatives | |
KR102374788B1 (ko) | 아르기나제 저해제 및 이의 치료적 용도 | |
KR102376248B1 (ko) | 삼환성 스피로 화합물 | |
JP2020523418A (ja) | Il−17調節剤としてのスピロ環インドリン | |
AU2020232026A1 (en) | Carboxamide-pyrimidine derivatives as shp2 antagonists | |
AU2017279029A1 (en) | Chemical compounds as ATF4 pathway inhibitors | |
JP7166028B2 (ja) | 高活性stingタンパク質アゴニスト化合物 | |
AU2016308717A1 (en) | Heteroaryl derivatives as PARP inhibitors | |
CA3185888A1 (en) | Brm targeting compounds and associated methods of use | |
WO2018104305A1 (en) | Field of application of the invention | |
EP3617204A1 (en) | Indoleamine 2,3-dioxygenase inhibitor and application | |
JP6922712B2 (ja) | 医薬用途 | |
WO2023244600A1 (en) | Prodrugs of pan-kras inhibitors | |
TW202321237A (zh) | Map4k1抑制劑 | |
WO2016012956A1 (en) | Isoquinolinone derivatives as parp inhibitors | |
JP2024534757A (ja) | Pd-l1相互作用の免疫調節剤としての化合物 |